Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
2.850
-0.020 (-0.70%)
Jan 17, 2025, 4:00 PM EST - Market closed
Lipella Pharmaceuticals Revenue
Lipella Pharmaceuticals had revenue of $80.38K in the quarter ending September 30, 2024, a decrease of -22.75%. This brings the company's revenue in the last twelve months to $483.53K, up 0.78% year-over-year. In the year 2023, Lipella Pharmaceuticals had annual revenue of $449.62K with 144.15% growth.
Revenue (ttm)
$483.53K
Revenue Growth
+0.78%
P/S Ratio
5.64
Revenue / Employee
$69,076
Employees
7
Market Cap
3.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 449.62K | 265.46K | 144.15% |
Dec 31, 2022 | 184.16K | -75.19K | -28.99% |
Dec 31, 2021 | 259.35K | -702.34K | -73.03% |
Dec 31, 2020 | 961.68K | 266.94K | 38.42% |
Dec 31, 2019 | 694.75K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
LIPO News
- 10 days ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - GlobeNewsWire
- 20 days ago - Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - GlobeNewsWire
- 4 weeks ago - Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - GlobeNewsWire
- 2 months ago - Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 4 months ago - PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - GlobeNewsWire
- 1 year ago - FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire